0. SK Life Science Introduction
2008. June

1. Holding company in SK Croup
Life Science in SK Group
Life Science Business is outset for the growth drive in the future
SK Group
Revenue: $ 848 MM
Employee > 300
Revenue: $ 1.2 B.
Employee > 1,150
SK holdings
SK Chemicals
Holding company in SK Croup
Fine Chemicals,
Life Science
Life Science Biz
Life Science Division
New Drug Development
Custom Manufacturing Service
Drug development & Marketing
(Korean and Asian Market)
1) E&P: Exploration & Production

2. SK Life Science
As of July 1st 2007, SK Corporation was divided into two companies, SK Energy and SK Holdings Ltd, and Life Science biz becomes a part of SK Holdings
Purpose of Reorganization
Solidifying Corporate Governance
Enhancing Overall Shareholder Value
Maximizing Management Efficiency
Resolving the Issue of Under-valuation
Previous Structure
New Structure
SK Corporation had various operating divisions and held many subsidiary companies
Reorganize as a holding company and 8 operating companies
SK Life Science stays with holding company as one operating division
Chemicals
E&P
Lubri- cants
SK Holdings
Life Science
Oil
Refinery
SK Corp.
SK Telecom
SK Networks
Other Subsidiaries
Life Science
SK Energy
SK Telecom
SK Networks
Other Subsidiaries

3. Drug Development Center (신약개발사업부)
Organization
Seoul, Korea
Daejeon, Korea
Shanghai, China
New Jersey, USA
SK Life Science Biz.
Life Science Strategy Team
Process R&D Lab.
Drug Development Center (신약개발사업부)
CMS Business (CMS사업부)
Discovery Lab.
CMS Production Team
Drug Preclinical Research Lab.
Marketing Team(New Jersey)
R&D Planning Team
New Jersey R&D Center
Shanghai R&D Center
* CMS: Custom Manufacturing Service

4. Drug Development Center

5. Drug Development Center
Role & Responsibility
Drug Development Center
KOREA
USA
CHINA
[Seoul]
Strategic Planning
Licensing Out
[LSRDP 1)]
R&D Planning
Licensing In
Drug Discovery
Early Preclinical Studies
Formulation Studies
Intellectual Properties
[New Jersey]
Advanced Preclinical Studies
Clinical Studies in USA
Regulatory Affairs in USA
[Shanghai]
Drug discovery
Market research in China
1) LSRDP: Life Science R&D Park

6. History The first Korean company to obtain IND approval from U.S. FDA
Licensing Out to Johnson & Johnson (CNS field)
Developing globally competitive new drug pipeline
Licensing Out
to J&J (YKP10A)
Start Pharmaceutical research in New Jersey, US and Daejeon, Korea focusing on CNS area
Licensing Out
to J&J (YKP509)
Establish Shanghai Drug Dev. Center
1996
1998
2003
2005
2007
1993
1999
2000
2002
IND Approval for YKP10A, an antidepressant, from U.S. FDA
IND Approval for YKP1358, an Antipsychotic, from U.S. FDA
New IND expected
IND Approval for YKP509, an anticonvulsant, from U.S. FDA
IND Approval for YKP3089, an anxiolytic, from U.S. FDA
(currently at POC entering)

7. R&D Areas CNS Successful track records in CNS drug discovery
Epilepsy, Depression, Schizophrenia, Neuropathic pain and Parkinson etc.
Expansion toward Metabolic diseases
Obesity, Diabetes and Osteoporosis
Transdermal
Controlled release
Intranasal Technology
DDS CV
Restenosis
Epilepsy
Depression
Schizophrenia
CNS
Metabolic
diseases
Neuropathic Pain
Parkinson
Obesity
Diabetes

8. Planning IND & Phase I in 2008
Pipeline Status
CNS
By J&J
Narcolepsy, Drug addiction
(Ready to IND)
on-going Preclinical studies w/
active enantiomer (YKP1447)
Planning IND & Phase I in 2008
Partnering Alliance - Clinical Study expected in May, 2008
DDS
Metabolic CV
Discovery
Lead
Preclinical
Phase I
Phase II
Phase III

9. CMS Business

10. Role & Responsibility CMS Business KOREA USA CHINA [Seoul] [LSRDP 1)]
Planning
[LSRDP 1)]
Production
Process Development
QC/QA
[New Jersey]
Marketing
Market Research
Customer Relationship
[Shanghai]
Process Development
Biz Development
Raw Material Purchasing
1) LSRDP: Life Science R&D Park

11. Overview
SK CMS provides custom manufacturing service to the global major pharma companies based on the innovative technological and production capabilities with a cGMP complied quality system
History & Location
Operation since 2000 based on R&D capabilities
Production Plants and R&D in Daejeon, Korea
Marketing in NJ, USA
Customers
Global Major Pharmaceutical Companies
Pfizer, Roche, Bristol-Meyers-Squibb, Schering Plough, Novartis, GSK, J&J, etc.
Technology
Catalytic Processes, Continuous Reaction Technologies
Enzymatic technology
Conventional Organic Synthesis
박준구 박사께 CMS의 자료를 받아서 소개에 어울리는 내용으로 바꿀 것!!!
Products & Services
GMP Intermediates and API (End of 2007)
Process development and DMF support for customers
Catalytic and Continuous Processes
Co-Work and DMF support
GMP (Good Manufacturing Practice)

12. Quality System Plant Operation based upon cGMP & ICH Q7A
Quality Assurance based on Quality Management Systems
Quality Management System
Material Control System
Facilities & Equipment System
Production & In-Process Control System
Laboratory Control System
Audits and Approval by Many Customers
’98 ~’01 GSK
’02 ~’03 Roche, Novartis, Pfizer
’04 ~’05 Pfizer, GSK, BMS, Lonza
’06 Pfizer, BMS (Approved for cGMP Intermediate Production)
Current Preparation of API Production and DMF Filing for New Drug

13. `08년 하반기 신입 사원 채용 모집분야 주요업무 모집인원 Process Chemist
유기합성 기술을 활용한 신약 후보물질 및 관련 중간체 제조 공정 개발 연구 0명
Process Engineer
신규 촉매 개발, 신규 연속공정 개발 업무

14. Thank you